The GLP-1 revolution: A double-edged sword in the fight against obesity
The GLP-1 drugs are a game-changer in the battle against obesity, but they come with a price. While they offer a promising solution to America's weight crisis, they also present a host of potential drawbacks and challenges.
The Rise of GLP-1s
The use of GLP-1 drugs in the US has skyrocketed, with nearly 11% of adults currently taking them for weight loss. This is a staggering increase from just 3% in 2024, and it coincides with a significant drop in obesity rates. The Gallup survey reveals a growing trend, with 15% of respondents reporting past use of these drugs, a nine-percentage-point jump in two years.
This surge in popularity is largely attributed to the approval of Wegovy by the FDA in 2021, which demonstrated impressive weight loss results. The market has since expanded with new players like Eli Lilly's Zepbound and Mounjaro, further fueling the trend. However, the gap between brand-name and compounded GLP-1s is narrowing, with affordability and coverage issues driving the shift.
The Next Frontier
The future of GLP-1s looks bright, with more convenient and potentially more powerful versions on the horizon. The FDA's approval of a daily pill version of Wegovy and Eli Lilly's orforglipron (Foundayo) in April 2026 marks a significant step forward. Additionally, Eli Lilly's retatrutide, a once-weekly injectable mimicking three hormones, is expected to seek FDA approval soon, with early data suggesting even greater weight loss potential.
The expanding applications of GLP-1s are also noteworthy. Wegovy's label now includes treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and reducing the risk of major cardiovascular events. Zepbound is the first FDA-approved medication for moderate-to-severe obstructive sleep apnea, and Ozempic is cleared for reducing the risk of worsening chronic kidney disease.
The Dark Side of GLP-1s
Despite their promise, GLP-1s are not without drawbacks. Common side effects include gastrointestinal problems like nausea, vomiting, diarrhea, and constipation. More severe complications, though rare, include pancreatitis, gallbladder disease, bowel obstruction, stomach paralysis, acute kidney injury, and vision problems.
The rapid weight loss associated with GLP-1s can also lead to challenges, such as loose or sagging skin, muscle loss, and the return or emergence of eating disorder symptoms. These drugs have been linked to a range of psychological and physical issues, raising questions about their long-term impact and the need for comprehensive patient support.
Conclusion: A Balanced Perspective
GLP-1s represent a significant advancement in the fight against obesity, offering a glimmer of hope for those struggling with weight-related issues. However, their potential drawbacks and side effects cannot be ignored. As these drugs continue to gain popularity, it is crucial to strike a balance between their benefits and risks, ensuring that patients receive the necessary support and education to make informed decisions.
